These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20046202)

  • 21. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
    Tsakonas E; Joseph L; Esdaile JM; Choquette D; Senécal JL; Cividino A; Danoff D; Osterland CK; Yeadon C; Smith CD
    Lupus; 1998; 7(2):80-5. PubMed ID: 9541091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs.
    Rahman P; Gladman DD; Urowitz MB; Yuen K; Hallett D; Bruce IN
    J Rheumatol; 1999 Feb; 26(2):325-30. PubMed ID: 9972966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
    Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM
    J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects.
    Tang C; Godfrey T; Stawell R; Nikpour M
    Intern Med J; 2012 Sep; 42(9):968-78. PubMed ID: 22827853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy of antimalarials in systemic lupus erythematosus.
    Esdaile JM
    Lupus; 1993 Feb; 2 Suppl 1():S3-8. PubMed ID: 8485568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimalarial therapy in SLE.
    Lanham JG; Hughes GR
    Clin Rheum Dis; 1982 Apr; 8(1):279-98. PubMed ID: 6749400
    [No Abstract]   [Full Text] [Related]  

  • 27. The efficacy of antimalarials in systemic lupus erythematosus.
    Nayak V; Esdaile JM
    Lupus; 1996 Jun; 5 Suppl 1():S23-7. PubMed ID: 8803906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Disseminated lupus erythematosus. The continued efficacy of hydroxychloroquine scientifically proven by default].
    Carette S
    Union Med Can; 1991; 120(5):360-4. PubMed ID: 1962386
    [No Abstract]   [Full Text] [Related]  

  • 29. Hydroxychloroquine Inhibits the Differentiation of Th17 Cells in Systemic Lupus Erythematosus.
    Yang J; Yang X; Yang J; Li M
    J Rheumatol; 2018 Jun; 45(6):818-826. PubMed ID: 29545450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New and Established Therapeutic Options for the Treatment of Systemic Lupus Erythematosus].
    Goehner Schweizer K; Maurer B
    Praxis (Bern 1994); 2020; 109(5):341-345. PubMed ID: 32233759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The multi-targets mechanism of hydroxychloroquine in the treatment of systemic lupus erythematosus based on network pharmacology.
    Xie B; Geng Q; Xu J; Lu H; Luo H; Hu Y; Song X
    Lupus; 2020 Nov; 29(13):1704-1711. PubMed ID: 32854577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada.
    Keeling SO; Bissonauth A; Bernatsky S; Vandermeer B; Fortin PR; Gladman DD; Peschken C; Urowitz MB
    J Rheumatol; 2018 Oct; 45(10):1440-1447. PubMed ID: 30068762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroxychloroquine: a multifaceted treatment in lupus.
    Costedoat-Chalumeau N; Dunogué B; Morel N; Le Guern V; Guettrot-Imbert G
    Presse Med; 2014 Jun; 43(6 Pt 2):e167-80. PubMed ID: 24855048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exacerbations of bipolar disorder triggered by chloroquine in systemic lupus erythematosus--a case report.
    Bogaczewicz J; Sobów T; Bogaczewicz A; Robak E; Bienkowski P; Sysa-Jedrzejowska A; Wozniacka A
    Lupus; 2014 Feb; 23(2):188-93. PubMed ID: 24297641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relapsed hydroxychloroquine induced thrombocytopenia in a systemic lupus erythematosus patient.
    Antón Vázquez V; Pascual L; Corominas H; Giménez Torrecilla I
    Reumatol Clin; 2017; 13(5):294-296. PubMed ID: 27263963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
    Fasano S; Pierro L; Pantano I; Iudici M; Valentini G
    J Rheumatol; 2017 Jul; 44(7):1032-1038. PubMed ID: 28507183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission.
    Zen M; Saccon F; Gatto M; Montesso G; Larosa M; Benvenuti F; Iaccarino L; Doria A
    Rheumatology (Oxford); 2020 Jul; 59(7):1591-1598. PubMed ID: 31642908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimalarial drug-induced aquagenic-type pruritus in patients with lupus.
    Jiménez-Alonso J; Tercedor J; Jáimez L; García-Lora E
    Arthritis Rheum; 1998 Apr; 41(4):744-5. PubMed ID: 9550488
    [No Abstract]   [Full Text] [Related]  

  • 39. A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye.
    Costedoat-Chalumeau N; Dunogué B; Leroux G; Morel N; Jallouli M; Le Guern V; Piette JC; Brézin AP; Melles RB; Marmor MF
    Clin Rev Allergy Immunol; 2015 Dec; 49(3):317-26. PubMed ID: 25672591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimalarial therapy: a panacea for mild lupus?
    D'Cruz D
    Lupus; 2001; 10(3):148-51. PubMed ID: 11315343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.